A recent study has shown a nearly fourfold increase in a rare form of breast cancer associated with estrogen/progestin hormone replacement therapy. The rare form of breast cancer is known as lobular breast cancer and accounts for only 15% of invasive breast cancers diagnosed worldwide.

The attorneys at Carey and Danis are prepared to represent victims of this rare form of breast cancer who were taking combined estrogen/progestin hormone replacement therapy for three years of more.

Previous studies had shown that there was an increased risk of cancer associated with estrogen/progestin hormone replacement therapy following five years or greater of use. However, this new study, published in Cancer Epidemiology, Biomarkers and Prevention in January shed light on the exposure time associated with an increased risk, particularly of an increased risk of lobular breast cancer.

The lawyers at Carey and Danis have represented numerous victims of pharmaceutical products in the past and are committed to aggressively pursuing compensation for their clients who took estrogen/progestin hormone replacement therapy drugs for three years or more and were diagnosed with lobular breast cancer.

If you or anyone you know was diagnosed with lobular breast cancer after taking estrogen/progestin hormone replacement therapy drugs for three years or more; contact the experienced lawyers at Carey and Danis immediately to discuss your case.